secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2026-06-17T20:15:28+00:00
Accession:  0001104659-26-075151
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aprea shareholders approve reverse stock split (1:3–1:8); all director nominees elected
--------------------------------------------------------------------------------

- All three Class I director nominees (Duey, Peters, Seizinger) elected; each received >5.4M votes for.
- Reverse stock split ratio between 1:3 and 1:8 approved (8.0M for, 210K against); board may effect at its discretion.
- Ratification of EisnerAmper as independent auditor for FY2026 passed with 8.1M votes for.
- Non-binding say-on-pay passed; advisory vote on frequency favored every 1 year (4.3M votes).
- Adjournment proposal also approved with 8.1M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/0001104659-26-075151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/tm2618205d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-075151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer